Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jul 8;9(13):3331-3335.
doi: 10.1182/bloodadvances.2024015344.

Restarting teclistamab and talquetamab after prolonged dose delay may not require re-step-up dosing

Carlyn Rose Tan  1 , Alice Wang  2 , David Nemirovsky  3 , Andriy Derkach  3 , Tala Shekarkhand  1 , Issam Hamadeh  2 , Kylee Maclachlan  1 , Malin Hultcrantz  1 , Hani Hassoun  1 , Sham Mailankody  1 , Alexander Lesokhin  1 , Urvi A Shah  1 , Sridevi Rajeeve  1 , Hamza Hashmi  1 , Dhwani Patel  1 , Ross Firestone  1 , Eric Jurgens  1 , Kevin Miller  1 , Gunjan L Shah  4 , Michael Scordo  4 , Heather J Landau  4 , Sergio A Giralt  4 , Neha Korde  1 , Saad Z Usmani  1
Affiliations

Restarting teclistamab and talquetamab after prolonged dose delay may not require re-step-up dosing

Carlyn Rose Tan et al. Blood Adv. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: C.R.T. reports research funding from Janssen and Takeda; personal fees from MJH Life Sciences; and has received honoraria for consultancy/participating in the advisory boards for Janssen and Sanofi. T.S. reports receiving honoraria from Roche-Genentech. K. Maclachlan reports grant support from American Society of Hematology, Multiple Myeloma Research Foundation, and International Myeloma Society. M.H. reports research funding from GlaxoSmithKline (GSK), BeiGene, AbbVie, and Daiichi Sankyo, and has received honoraria for consultancy/participated in the advisory boards for Curio Science LLC, Intellisphere LLC, Bristol Myers Squibb (BMS), Janssen, and GSK. S.M. reports research funding from the National Cancer Institute, Janssen Oncology, BMS, Allogene Therapeutics, Fate Therapeutics, Caribou Therapeutics, and Takeda Oncology; has received consulting fees from EviCore, Optum, Bio Ascend, Janssen Oncology, BMS, AbbVie, HMP Education, and Legend Biotech; and has received honoraria from OncLive, Physician Education Resource, MJH Life Sciences, and Plexus Communications. H. Hassoun reports grants from Celgene, Takeda, and Janssen, outside the submitted work. A.L. reports nonfinancial support from Pfizer; grants and personal fees from Janssen, outside the submitted work; serves on the data safety monitoring board for Arcellx; and also has a patent US20150037346A1 with royalties paid. U.A.S. reports research support from Celgene/BMS and Janssen (to the institution); nonfinancial research support from Sabinsa pharmaceuticals and M&M Labs (to the institution); and personal fees from, Janssen Biotech, Sanofi, BMS, and i3 Health, outside the submitted work. H. Hashmi reports consultancy for Karyopharm, Amgen, and Janssen. G.L.S. receives research funding from Janssen, Amgen, BMS, Beyond Spring; serves on the data safety monitoring board for Arcellx; and receives research funding to the institution from Janssen, Amgen, BMS, Beyond Spring, and GPCR. M.S. served as a paid consultant for McKinsey & Company, Angiocrine Bioscience Inc, and Omeros Corporation; received research funding from Angiocrine Bioscience Inc, Omeros Corporation, Amgen Inc, BMS, and Sanofi; served on ad hoc advisory boards for Kite (a Gilead company) and Miltenyi Biotec; and received honoraria from i3 Health, Medscape, Cancer Network, and IDEOlogy. H.J.L. has served as a paid consultant for AbbVie, Immix Biopharma, Legend Biotech, Alexion, Prothena, and has received research funding from Nexcella, Janssen, Alexion, Protego, and Prothena. S.A.G. reports personal fees from and advisory role with (scientific advisory board) Actinium, Celgene, BMS, Sanofi, Amgen, Pfizer, GSK, Jazz, Janssen, Omeros, Takeda, and Kite, outside the submitted work. N.K. reports research funding through Amgen, Janssen, Epizyme, AbbVie; consults for Clinical Care Options, OncLive, and Intellisphere Remedy Health; and participated in advisory board for Janssen and MedImmune. S.Z.U. received research funding from Amgen, AbbVie, Array Biopharma, BMS, Celgene, Gilead, GSK, Janssen, Merck, Pharmacyclics, Sanofi, Seattle Genetics, SkylineDx, and Takeda; is a consultant to AbbVie, Amgen, BMS, Celgene, Edo Pharma, Genentech, Gilead, GSK, Gracell, Janssen, Oncopeptides, Pfizer, Sanofi, Seattle Genetics, Secura Bio, SkylineDx, Takeda, and TeneoBio; and is a speaker for Amgen, BMS, Janssen, and Sanofi. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
A swimmer plot for patients treated with teclistamab or talquetamab, colored by treatment response according to International Myeloma Working Group response criteria, prior to prolonged dose-delay event(s) and after reinitiation of bispecific antibody therapy. CR, complete response; LDH, lactate dehydrogenase; NE, not evaluable; PD, progressive disease; PR, partial response; sCR, stringent complete response; SD, stable disease; VGPR, very good partial response.
See this image and copyright information in PMC

References

    1. Moreau P, Garfall AL, van de Donk NWCJ, et al. Teclistamab in relapsed or refractory multiple myeloma. N Engl J Med. 2022;387(6):495–505. - PMC - PubMed
    1. Garfall AL, Nooka AK, Donk NWCJvd, et al. Long-term follow-up from the phase 1/2 MajesTEC-1 Trial of teclistamab in patients with relapsed/refractory multiple myeloma. J Clin Oncol. 2024;42(suppl 16):7540.
    1. Chari A, Minnema MC, Berdeja JG, et al. Talquetamab, a T-cell-redirecting GPRC5D bispecific antibody for multiple myeloma. N Engl J Med. 2022;387(24):2232–2244. - PubMed
    1. van de Donk NWCJ, Chari A, Karlin L, et al. Analysis of repeat step-up dosing and cytokine release syndrome events following prolonged dosing intervals of teclistamab in the phase 1/2 majestec-1 study. Blood. 2024;144(suppl 1):4734.